Signed binding term sheet granting Intact Therapeutics an exclusive option to license PCS12852 Continue enrolling patients in Phase 2 study of PCS6422 Strengthened balance sheet with $7M capital ...
TipRanks on MSN
Processa Pharmaceuticals Approves Key Shareholder Proposals
Processa Pharmaceuticals ( ($PCSA) ) has issued an update. Processa Pharmaceuticals held a Special Meeting of Shareholders on September 11, 2025, ...
VERO BEACH, Fla., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (PCSA), a clinical-stage biopharmaceutical company developing Next Generation Cancer (NGC) therapies for cancer ...
HANOVER, Md., June 17, 2025 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), today announced that it has entered into a binding term sheet with Intact Therapeutics, Inc. (“Intact”) ...
Processa Pharmaceuticals ( ($PCSA) ) has issued an announcement. On September 2, 2025, Processa Pharmaceuticals held a Special Shareholder Meeting ...
BFRG: https://www.redchip.com/assets/access/bfrg_access.html In an exclusive interview, George Ng, CEO of Processa Pharmaceuticals, appears on the RedChip Small ...
ORLANDO, FLORIDA / ACCESS Newswire / July 18, 2025 / RedChip Companies will air interviews with Processa Pharmaceuticals, Inc. (Nasdaq:PCSA) and BullFrog AI, Inc. (Nasdaq:BFRG) on the RedChip Small ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback